CHMP konkluderede, at fordelene ved Prepandrix er større end risiciene ved aktiv immunisering mod influenzavirus type A, subtype H5N1.
The CHMP decided that Prepandrix’ s benefits are greater than its risks for active immunisation against H5N1 subtype of influenza A virus.